Beam Therapeutics Inc. (BEAM) News

Beam Therapeutics Inc. (BEAM): $32.23

-0.99 (-2.98%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BEAM to Watchlist
Sign Up

Industry: Biotech


Ranked

of 385

in industry

Filter BEAM News Items

BEAM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BEAM News Highlights

  • BEAM's 30 day story count now stands at 11.
  • Over the past 21 days, the trend for BEAM's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about BEAM are BASE, GENE and DRUG.

Latest BEAM News From Around the Web

Below are the latest news stories about BEAM THERAPEUTICS INC that investors may wish to consider to help them evaluate BEAM as an investment opportunity.

Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference

CAMBRIDGE, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, Ph.D., president of Beam, will participate in a fireside chat during the Barclays 2023 Global Healthcare Conference on Thursday, March 16, 2023 at 8:30 a.m. ET in Miami, FL. A live webcast will be available in the investor section of the company's website at www.beamtx.com, and wi

Yahoo | March 15, 2023

3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing

CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals are three CRISPR gene editing stocks you won't want to miss out on.

John Blankenhorn on InvestorPlace | March 6, 2023

Industry Analysts Just Upgraded Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts By 17%

Beam Therapeutics Inc. ( NASDAQ:BEAM ) shareholders will have a reason to smile today, with the analysts making...

Yahoo | March 5, 2023

3 Game-Changing Stocks to Buy in March

Three Motley Fool contributors were asked to select stocks to buy in March that truly are game changers. Here's why they picked Beam Therapeutics (NASDAQ: BEAM), CRISPR Therapeutics (NASDAQ: CRSP), and Vertex Pharmaceuticals (NASDAQ: VRTX). Keith Speights (Beam Therapeutics): Base editing is an approach to editing genes invented in 2016 by a team led by David Liu.

Yahoo | March 4, 2023

The Top 7 Growth Stocks in Biotech

The biotech sector always houses a great selection of growth stocks that can grow rapidly and reward investors over the long-term.

Alex Sirois on InvestorPlace | March 3, 2023

15 Most Shorted Stocks Right Now on Wall Street

In this article, we will look at the 15 most shorted stocks on Wall Street right now. If you want to explore similar stocks, you can also take a look at 5 Most Shorted Stocks Right Now on Wall Street. Short selling is a way for traders to make money by betting that the price […]

Yahoo | March 3, 2023

Beam Therapeutics to Participate in the 43rd Annual Cowen Healthcare Conference

CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a panel titled, “Gene Editing Corporate Panel” during the 43rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET in Boston. A live webcast will be available in the investor section of the company's website at www.be

Yahoo | March 1, 2023

Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 59.09% and 69.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 28, 2023

Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones

Advancing Pipeline of Wholly Owned Base Editing Therapeutics with Four Development-stage Programs Expanding Investment in a Broad Portfolio of Potential New Programs Designed to Extend Reach of Base Editing Medicines North Carolina Manufacturing Facility Open and Operational, Expected to Commence cGMP Operations in Late 2023 Ended Fourth Quarter 2022 with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (N

Yahoo | February 28, 2023

10 Most Promising Biotech Stocks According to Analysts

In this article, we discuss 10 most promising biotech stocks according to analysts. If you want to see more stocks in this selection, check out 5 Most Promising Biotech Stocks According to Analysts. Last year was a period of transition for biotech firms. Following significant investment, the availability of cheap capital, and public recognition for […]

Yahoo | February 25, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.684 seconds.